Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Institute of Digestive Diseases, Tianjin Key Laboratory of Digestive Diseases, Tianjin 300052, China; School of Health, Binzhou Polytechnic, Binzhou, China.
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Institute of Digestive Diseases, Tianjin Key Laboratory of Digestive Diseases, Tianjin 300052, China.
Biomed Pharmacother. 2024 Sep;178:117197. doi: 10.1016/j.biopha.2024.117197. Epub 2024 Jul 30.
The steady increase in the prevalence of inflammatory bowel disease (IBD) is regarded as a worldwide health issue. Gut microorganisms could modulate host immune and metabolic status and are associated with health effects. Probiotics, Lactobacillus rhamnosus GG (LGG), are beneficial microorganisms that ameliorate disease and exert advantageous effects on intestinal homeostasis. However, the viability of probiotics will suffer from various risk factors in the digestive tract. In this view, we developed a probiotic coating with nanocomposite using tannic acid (TA) and casein phosphopeptide (CPP) through layer-by-layer technology to overcome the challenges after oral administration. LGG showed an improved survival rate in simulated gastrointestinal conditions after coated. The coating (LGG/TA-Mg/CPP) had potent reactive oxygen species (ROS) scavenging ability and improved the survival rate of colorectal epithelial cells after HO stimulation. In DSS-induced colitis, administration of LGG/TA-Mg/CPP ameliorated intestinal inflammation and reduced the disruption of barrier function. Furthermore, LGG/TA-Mg/CPP increased the abundance and diversity of the gut microbiota. In the mouse model of DSS colitis, LGG/TA-Mg/CPP can better activate the EGFR/AKT signaling pathway, thereby protecting the epithelial barrier function of the colon epithelium. In conclusion, the probiotic coating with nanocomposite may become a delivery platform for probiotics applied to IBD.
炎症性肠病(IBD)的患病率稳步上升,被认为是一个全球性的健康问题。肠道微生物可以调节宿主的免疫和代谢状态,并与健康效应有关。益生菌、鼠李糖乳杆菌 GG(LGG)是有益的微生物,可以改善疾病,并对肠道内稳态发挥有利作用。然而,益生菌的存活率会受到消化道中各种危险因素的影响。有鉴于此,我们通过层层技术,使用单宁酸(TA)和酪蛋白磷酸肽(CPP)开发了一种益生菌纳米复合涂层,以克服口服后带来的挑战。经过涂层处理后,LGG 在模拟胃肠道条件下的存活率提高。该涂层(LGG/TA-Mg/CPP)具有很强的清除活性氧(ROS)的能力,并能提高 HO 刺激后结肠上皮细胞的存活率。在 DSS 诱导的结肠炎中,LGG/TA-Mg/CPP 可改善肠道炎症,减少屏障功能的破坏。此外,LGG/TA-Mg/CPP 增加了肠道微生物群的丰度和多样性。在 DSS 结肠炎的小鼠模型中,LGG/TA-Mg/CPP 可以更好地激活 EGFR/AKT 信号通路,从而保护结肠上皮的上皮屏障功能。总之,这种益生菌纳米复合涂层可能成为应用于 IBD 的益生菌的一种输送平台。